Therapeutic or prophylactic agent for diabetes
AssigneesThe University of Tokyo, Toray Industries, Inc.
InventorsTakehiro Takahashi, Hiroki Kumagai, Takashi Kadowaki, Naoto Kubota, Tetsuya Kubota
Life of this patent
Estimating the term…
Loading patent…
AssigneesThe University of Tokyo, Toray Industries, Inc.
InventorsTakehiro Takahashi, Hiroki Kumagai, Takashi Kadowaki, Naoto Kubota, Tetsuya Kubota
Estimating the term…
A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.
A therapeutic or prophylactic agent for diabetes, comprising a combination of a prostaglandin I2 derivative represented by Formula (I):
A method of treating diabetes comprising administering 1) a prostaglandin I2 derivative represented by Formula (I):
Dependencies are inferred from the claim text.